

## Special Issue

# Recent Progress in Leukemia: Where Do We Stand?

### Message from the Guest Editors

Recent drug development and advances in biology have altered the therapeutic treatment of leukemia patients. Treatment options for different types of leukemias now include targeted therapies, immune-based therapeutics, and multiple novel modalities that are currently under investigation. Additionally, novel drugs approved in the last 5 years have drawn attention to new situations and treatable patient sub-groups. Nowadays, modern leukemia therapy decisions mainly rely on the selection of patients suitable for specific targeted agents; thus, the assessment of disease- and patient-specific factors deserves special consideration. In AML, recent discoveries of the role of molecular drivers of leukemogenesis and disease progression have led to the development of innovative therapeutic strategies. This knowledge translates into newer algorithms, focusing on appropriate patients eligible for intensive or non-intensive treatments. In this Special Issue in the *Journal of Clinical Medicine*, we welcome authors to submit papers on the clinical advances of CLL and AML.

### Guest Editors

Dr. Stefano Molica

Department of Haematology, Hull University Teaching Hospitals NHS Trust, Hull, UK

Dr. Marco Rossi

1. Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, 88100 Catanzaro, Italy

2. Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy

### Deadline for manuscript submissions

closed (20 December 2023)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/169414](https://mdpi.com/si/169414)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://www.mdpi.com/journal/jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com/)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).